|
ErstIVX, dann WPI, jetzt PRX und ADRX NEW YORK, Feb 20 (Reuters) - Shares of Pharmaceutical Resources Inc.(NYSE:PRX - news) plunged on Wednesday after the generic drugmaker said sales of one of its biggest money-makers, a treatment for anorexia, could be hurt by a newly approved rival generic treatment. Pharmaceutical Resources (PRI) said Roxane Laboratories, the U.S. subsidiary of privately held German company Boehringer Ingelheim Corp., won U.S. approval last Friday to sell an oral suspension form of megestrol, a treatment for anorexia and for people with AIDS who have lost a great deal of weight. NEW YORK (Reuters) - Shares of Andrx Corp. tumbled on Friday after the generic drugmaker reported a larger-than-expected drop in fourth-quarter earnings after legal and regulatory obstacles delayed its introduction of new copycat medicines. |
|
| aus der Diskussion: | generics |
| Autor (Datum des Eintrages): | southbound (23.02.02 13:44:30) |
| Beitrag: | 60 von 125 (ID:5657239) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |